A
Anthony Vattay
Researcher at Novartis
Publications - 9
Citations - 1160
Anthony Vattay is an academic researcher from Novartis. The author has contributed to research in topics: Smoothened & Smoothened Receptor. The author has an hindex of 5, co-authored 9 publications receiving 1013 citations.
Papers
More filters
Journal ArticleDOI
Interfering with Resistance to Smoothened Antagonists by Inhibition of the PI3K Pathway in Medulloblastoma
Silvia Buonamici,Juliet Williams,Michael Morrissey,Anlai Wang,Ribo Guo,Anthony Vattay,Kathy Hsiao,Jing Yuan,John Green,Beatriz Ospina,Qunyan Yu,Lance Ostrom,Paul Fordjour,Dustin L. Anderson,John Monahan,Joseph Kelleher,Stefan Peukert,Shifeng Pan,Xu Wu,Sauveur Michel Maira,Carlos Garcia-Echeverria,Kimberly J. Briggs,D. Neil Watkins,Yung Mae Yao,Christoph Lengauer,Markus Warmuth,William R. Sellers,Marion Dorsch +27 more
TL;DR: By identifying a drug combination that delays or even combats development of resistance when used as a first-line treatment in clinical trials, these results could ultimately improve the lives of patients with medulloblastoma or other cancers that depend on Smo for their survival.
Journal ArticleDOI
Discovery of NVP-LDE225, a Potent and Selective Smoothened Antagonist
Shifeng Pan,Xu Wu,Jiqing Jiang,Wenqi Gao,Yongqin Wan,Dai Cheng,Dong Han,Jun Liu,Nathan P. Englund,Yan Wang,Stefan Peukert,Karen Miller-Moslin,Jing Yuan,Ribo Guo,Melissa Matsumoto,Anthony Vattay,Yun Jiang,Jeffrey Tsao,Fangxian Sun,AnneMarie Culazzo Pferdekamper,Stephanie Kay Dodd,Tove Tuntland,Wieslawa Maniara,Joseph Kelleher,Yung-mae Yao,Markus Warmuth,Juliet Williams,Marion Dorsch +27 more
TL;DR: Structural-activity relationship studies led to the discovery of a potent and specific Smoothened antagonist N-(6-((2S,6R)-2,6-dimethylmorpholino)pyridin-3-yl)-2-methyl-4'-(trifluoromethoxy)biphenyl- 3-carboxamide (5m, NVP-LDE225), which is currently in clinical development.
Journal ArticleDOI
1-amino-4-benzylphthalazines as orally bioavailable smoothened antagonists with antitumor activity.
Karen Miller-Moslin,Stefan Peukert,Rishi K. Jain,Michael A Mcewan,Rajesh Karki,Luis Llamas,Naeem Yusuff,Feng He,Yanhong Li,Yingchuan Sun,Miao Dai,Lawrence Blas Perez,Walter Michael,Tao Sheng,Lei Huangshu,Rui Zhang,Juliet Williams,Aaron Bourret,Arun Ramamurthy,Jing Yuan,Ribo Guo,Melissa Matsumoto,Anthony Vattay,Wieslawa Maniara,Adam Amaral,Marion Dorsch,Joseph Kelleher +26 more
TL;DR: A cell-based screen performed in the laboratories identified a new class of Hh pathway inhibitors, 1-amino-4-benzylphthalazines, that act via antagonism of the Smoothened receptor that displayed a good pharmacokinetic profile and also afforded tumor regression in a genetic mouse model of medulloblastoma.
Journal ArticleDOI
Discovery of Orally Active Inhibitors of Brahma Homolog (BRM)/SMARCA2 ATPase Activity for the Treatment of Brahma Related Gene 1 (BRG1)/SMARCA4-Mutant Cancers
Julien Papillon,Katsumasa Nakajima,Christopher D. Adair,Jonathan E. Hempel,Andriana Jouk,Rajeshri Ganesh Karki,Simon Mathieu,Henrik Möbitz,Rukundo Ntaganda,Troy Smith,Michael Scott Visser,Susan E. Hill,Felipe Kellermann Hurtado,Gregg Chenail,Hyo-eun C. Bhang,Anka Bric,Kay Xiang,Geoffrey Bushold,Tamara J. Gilbert,Anthony Vattay,Julie Dooley,Emily A. Costa,Isabel Park,Ailing Li,David Farley,Eugen Lounkine,Q. Kimberley Yue,Xiaoling Xie,Xiaoping Zhu,Raviraj Kulathila,Daniel King,Tiancen Hu,Katarina Vulic,John Cantwell,Catherine Luu,Zainab Jagani +35 more
TL;DR: Allosteric dual BRM and BRG1 inhibitors that downregulate BRM-dependent gene expression and show antiproliferative activity in aBRG1-mutant-lung-tumor xenograft model upon oral administration are described.
Journal ArticleDOI
Discovery of NVP-LEQ506, a Second-Generation Inhibitor of Smoothened
Stefan Peukert,Feng He,Miao Dai,Rui Zhang,Yingchuan Sun,Karen Miller-Moslin,Michael A Mcewan,Bharat Lagu,Kate Wang,Naeem Yusuff,Aaron Bourret,Arun Ramamurthy,Wieslawa Maniara,Adam Amaral,Anthony Vattay,Anlai Wang,Ribo Guo,Jing Yuan,John Green,Juliet Williams,Silvia Buonamici,Joseph Kelleher,Marion Dorsch +22 more
TL;DR: This new agent combines high intrinsic potency and good pharmacokinetic properties resulting in excellent efficacy in preclinical rodent tumor models of medulloblastoma.